Karius Inc., a California-based health tech company focusing on genomic diagnostics in Infectious disease, has secured $100 million in Series C funding to expand its reach across the United States. According to the company’s announcement on Thursday, May 2, 2024, the funding round was co-led by Khosla Ventures, alongside new investors Gilde Healthcare and 5AM Ventures. Karius will use the additional $100 million to expand access to advanced genomic diagnostics in infectious diseases to more patients and address the antimicrobial resistance crisis.
read more..